RHBDF2 (iRhom2) Protein

<div class="infobox infobox-protein">
<div class="infobox-header">RHBDF2 (iRhom2) — Inactive Rhomboid 2</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Gene Symbol:</strong> RHBDF2</div>
<div class="infobox-row"><strong>Protein Name:</strong> Inactive rhomboid protein 2 (iRhom2)</div>
<div class="infobox-row"><strong>Alternative Names:</strong> RHBDF2, iRhom2, rho, SARAH domain-containing protein</div>
<div class="infobox-row"><strong>UniProt ID:</strong> <a href="https://www.uniprot.org/uniprot/Q8IWP4" target="_blank">Q8IWP4</a></div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 84102</div>
<div class="infobox-row"><strong>Protein Length:</strong> 572 amino acids</div>
<div class="infobox-row"><strong>Molecular Weight:</strong> ~75 kDa</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 17q25.1</div>
<div class="infobox-row"><strong>PDB Structures:</strong> 5IX2, 5W5U</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Endoplasmic reticulum, plasma membrane</div>
<div class="infobox-row"><strong>Protein Family:</strong> Rhomboid protease family (inactive pseudoprotease)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's disease, Parkinson's disease, Keratitis-ichthyosis-deafness syndrome, Inflammatory disorders[@wang2018]</div>
</div>
</div>

RHBDF2 (iRhom2) Protein

Overview

<div class="infobox infobox-protein">
<div class="infobox-header">RHBDF2 (iRhom2) — Inactive Rhomboid 2</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Gene Symbol:</strong> RHBDF2</div>
<div class="infobox-row"><strong>Protein Name:</strong> Inactive rhomboid protein 2 (iRhom2)</div>
<div class="infobox-row"><strong>Alternative Names:</strong> RHBDF2, iRhom2, rho, SARAH domain-containing protein</div>
<div class="infobox-row"><strong>UniProt ID:</strong> <a href="https://www.uniprot.org/uniprot/Q8IWP4" target="_blank">Q8IWP4</a></div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 84102</div>
<div class="infobox-row"><strong>Protein Length:</strong> 572 amino acids</div>
<div class="infobox-row"><strong>Molecular Weight:</strong> ~75 kDa</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 17q25.1</div>
<div class="infobox-row"><strong>PDB Structures:</strong> 5IX2, 5W5U</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Endoplasmic reticulum, plasma membrane</div>
<div class="infobox-row"><strong>Protein Family:</strong> Rhomboid protease family (inactive pseudoprotease)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's disease, Parkinson's disease, Keratitis-ichthyosis-deafness syndrome, Inflammatory disorders[@wang2018]</div>
</div>
</div>

RHBDF2 (iRhom2) Protein

Overview

RHBDF2 (Rhomboid Family Member 2), also known as iRhom2 (inactive rhomboid 2), is a polytopic membrane protein that belongs to the rhomboid family of intramembrane proteases. However, unlike its family members, iRhom2 is catalytically inactive and functions primarily as a molecular scaffold and regulatory protein rather than a protease. Located on chromosome 17q25.1 and encoding a 572 amino acid protein, iRhom2 has emerged as a critical regulator of inflammation, epidermal growth factor (EGF) signaling, and innate immune responses [1][2].

The protein's functions have significant implications for neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), where chronic neuroinflammation plays a central role in disease pathogenesis. iRhom2 acts as a master regulator of TNF-α converting enzyme (TACE/ADAM17), controlling the release of soluble TNF-α and other pro-inflammatory cytokines from immune cells. This position at the intersection of inflammation and cellular signaling makes iRhom2 an attractive therapeutic target [3][4].

Structure and Evolution

Domain Architecture

iRhom2 possesses the characteristic rhomboid fold but lacks catalytic activity:

| Domain | Residues | Function |
|--------|----------|----------|
| N-terminal cytosolic domain | 1-150 | Contains regulatory motifs, protein interaction sites |
| Transmembrane domain 1 | 151-173 | Membrane spanning |
| Transmembrane domain 2 | 185-207 | Membrane spanning |
| Transmembrane domain 3 | 218-240 | Membrane spanning |
| Transmembrane domain 4 | 252-274 | Membrane spanning |
| transmembrane domain 5 | 286-308 | Membrane spanning |
| Transmembrane domain 6 | 320-342 | Membrane spanning |
| Rhomboid core domain | 150-400 | Conserved rhomboid fold (inactive) |
| C-terminal cytosolic domain | 400-572 | Contains proline-rich motifs |

Catalytic Inactivity

The rhomboid family originally comprised active serine proteases that cleave substrates within transmembrane domains. However, iRhom2 has lost its catalytic activity through evolution:

• Active site mutation: The catalytic serine is replaced by a non-functional residue
• Substrate-binding pocket: Retained but used for protein-protein interactions rather than catalysis
• Evolutionary conservation: The pseudoprotease function has been co-opted for regulatory roles

Structural Features

Key structural elements include:

Normal Physiological Functions

Regulation of TACE/ADAM17

The primary function of iRhom2 is as a master regulator of TACE (TNF-α converting enzyme), also known as ADAM17 (A Disintegrin and Metalloproteinase 17):

Mechanism of TACE Regulation:

TACE Substrates:
iRhom2-controlled TACE activity releases numerous bioactive molecules:

| Substrate | Function | Relevance to Neurodegeneration |
|-----------|----------|-------------------------------|
| TNF-α | Pro-inflammatory cytokine | Neuroinflammation |
| L-selectin | Leukocyte adhesion | Immune cell trafficking |
| TGF-α | EGFR ligand | Cell proliferation |
| Amphiregulin | EGFR ligand | Tissue repair |
| Notch | Developmental signaling | Neural development |
| Amyloid precursor protein (APP) | Precursor to Aβ | Alzheimer's disease |

EGF Receptor Signaling

iRhom2 regulates EGFR ligand shedding through TACE:

• EGF ligands: TGF-α, amphiregulin, epiregulin, heparin-binding EGF
• Signal transduction: Controls cell proliferation, differentiation, survival
• Tissue homeostasis: Critical for epidermal maintenance and repair
• Dysregulation consequences: Contributes to cancer, inflammatory skin conditions

Immune Function

iRhom2 plays crucial roles in innate and adaptive immunity:

Innate Immunity:

• Controls TNF-α release from macrophages and monocytes
• Regulates inflammatory cytokine production
• Required for response to bacterial and viral pathogens
• Modulates inflammasome activity

• Affects T cell activation and function
• Regulates B cell development
• Controls inflammatory cell trafficking

Epidermal Function

iRhom2 is highly expressed in keratinocytes and skin:

• Required for normal epidermal homeostasis
• Controls skin inflammation
• Essential for wound healing
• Mutations cause skin barrier disorders

Expression Pattern

Tissue Distribution

iRhom2 exhibits broad expression:

| Tissue | Expression Level | Primary Cell Types |
|--------|-----------------|-------------------|
| Skin | Very high | Keratinocytes, fibroblasts |
| Immune system | High | Macrophages, monocytes, neutrophils |
| Brain | Moderate | Microglia, neurons (lower) |
| Liver | High | Hepatocytes |
| Lung | Moderate | Epithelial cells |
| Heart | Low-moderate | Cardiomyocytes |
| Spleen | High | Immune cells |

Subcellular Localization

• Endoplasmic reticulum: Primary site of iRhom2-TACE interaction
• Plasma membrane: Where TACE functions as sheddase
• Golgi apparatus: Intermediate in trafficking pathway
• Cytosol: C-terminal domain extends into cytosol

Role in Alzheimer's Disease

Neuroinflammation

iRhom2 contributes to Alzheimer's disease pathogenesis primarily through neuroinflammation:

TNF-α Mediated Inflammation:

• Elevated TNF-α in AD brain correlates with disease severity
• Chronic neuroinflammation drives tau pathology
• TNF-α promotes amyloid-beta production
• Contributes to synaptic dysfunction

• iRhom2 regulates microglial TNF-α release
• Contributes to chronic microglial activation
• Promotes pro-inflammatory microglial phenotype
• Impairs clearance of amyloid deposits

Amyloid Processing

iRhom2 may influence amyloid pathology through TACE-mediated APP processing:

• TACE can cleave APP at the α-secretase site
• This cleavage prevents amyloid-beta generation
• iRhom2 dysregulation may shift APP processing toward amyloidogenic pathway
• May affect amyloid plaque burden

Therapeutic Implications

Targeting the iRhom2-TACE axis in AD:

| Strategy | Approach | Status |
|----------|----------|--------|
| TACE inhibitors | Small molecule inhibitors | Preclinical |
| iRhom2 modulators | Target protein-protein interaction | Research |
| Anti-TNF therapies | Monoclonal antibodies | Clinical (failed in AD) |
| Downstream blockade | TNF receptor antagonists | Research |

Role in Parkinson's Disease

Neuroinflammation

iRhom2 contributes to Parkinson's disease through similar inflammatory mechanisms:

• Elevated TNF-α in PD substantia nigra
• Microglial activation surrounding dopaminergic neurons
• Pro-inflammatory cytokines promote neuron loss
• Chronic neuroinflammation drives disease progression

Glial Cell Function

iRhom2 in astrocytes and microglia:

• Regulates cytokine production
• Controls glial scar formation
• May affect neuron-glia interactions
• Modulates oxidative stress responses

Protein Aggregation

Emerging evidence suggests iRhom2 may influence α-synuclein aggregation:

• May affect cellular clearance pathways
• Could modulate protein homeostasis
• May influence lysosomal function

Disease Associations

Keratitis-Ichthyosis-Deafness (KID) Syndrome

Dominant mutations in RHBDF2 cause KID syndrome:

Clinical Features:

• Keratitis (corneal inflammation)
• Ichthyosis (scaly skin)
• Sensorineural hearing loss
• Increased risk of squamous cell carcinoma

• Gain-of-function mutations cause constitutive activation
• Leads to excessive inflammatory cytokine production
• Affects epidermal homeostasis

Inflammatory Disorders

iRhom2 variants associated with:

• Rheumatoid arthritis
• Inflammatory bowel disease
• Lupus
• Multiple sclerosis
• Psoriasis

Cancer

iRhom2 dysregulation in various cancers:

• Promotes tumor progression through EGFR signaling
• Supports cell proliferation
• May contribute to metastasis
• Potential therapeutic target

Interaction Network

Protein-Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| TACE/ADAM17 | Direct binding | Controls TACE trafficking and activity |
| ADAM10 | Indirect regulation | May affect other sheddases |
| EGFR | Downstream signaling | Via TACE-mediated ligand release |
| TNF-α | Indirect regulation | Via TACE substrate |
| iRhom1 | Homodimerization | Functional redundancy |
| Ubiquitin ligases | Regulatory | Controls protein stability |

Signaling Pathways

iRhom2 interfaces with multiple signaling pathways:

• NF-κB pathway: Downstream of TNF-α signaling
• MAPK pathway: Via EGFR signaling
• JAK-STAT pathway: Cytokine signaling
• Inflammasome pathways: Inflammatory activation

Genetic Variants

Disease-Causing Mutations

| Mutation Type | Effect | Disease |
|--------------|--------|---------|
| Missense (gain-of-function) | Constitutive activation | KID syndrome |
| Nonsense | Loss-of-function | Immune dysfunction |
| Frameshift | Loss-of-function | Inflammatory disease |
| Splice variants | Altered splicing | Various phenotypes |

Population Variants

• Common variants may influence inflammatory disease risk
• Expression quantitative trait loci (eQTLs) affect iRhom2 levels
• Some variants associated with autoimmune disease

Therapeutic Targeting

Rationale

iRhom2 is an attractive target because:

Therapeutic Strategies

Small Molecule Inhibitors:

• TACE inhibitors have been developed
• Challenges: specificity, side effects
• Limited efficacy in clinical trials

• Anti-TNF antibodies (etanercept, infliximab)
• Failed in AD trials
• May have narrower therapeutic window than expected

• Targeting iRhom2 expression
• siRNA-mediated knockdown
• CRISPR-based approaches

• Existing anti-inflammatory drugs
• TACE inhibitors from oncology
• Immunomodulatory compounds

Challenges

• Complexity of inflammatory networks
• Compensatory mechanisms
• Safety concerns with immunosuppression
• Blood-brain barrier penetration for CNS diseases

Research Models

Animal Models

• Knockout mice: iRhom2-deficient mice
• Transgenic mice: Overexpression models
• Conditional knockouts: Tissue-specific deletion

Cell Culture Models

• Macrophages: Primary and cell lines
• Microglia: Primary and immortalized
• Neurons: From iPSC differentiation
• Keratinocytes: Skin research

Experimental Techniques

• Biochemistry: Protein interaction studies
• Cell biology: Trafficking analysis
• Immunology: Cytokine measurements
• Neuroscience: Electrophysiology, imaging

Biomarkers and Diagnostics

Potential Biomarkers

• Soluble TNF-α levels
• iRhom2 expression in immune cells
• TACE activity measurements
• Inflammatory cytokine panels

Clinical Utility

• Disease progression markers
• Therapeutic response indicators
• Patient stratification for clinical trials

Key Publications

Cross-References

Related Proteins

• [TACE/ADAM17](/proteins/tace-protein) — TNF-α converting enzyme
• [EGFR](/proteins/egfr) — Epidermal growth factor receptor
• [TNF-α](/proteins/tnf-alpha) — Tumor necrosis factor alpha
• [ADAM10](/proteins/adam10-protein) — Related sheddase
• [iRhom1](/proteins/rhbdf1-protein) — Related pseudoprotease

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [KID Syndrome](/diseases/keratitis-ichthyosis-deafness-syndrome)

Related Mechanisms

• [Neuroinflammation](/mechanisms/neuroinflammation)
• [TNF-α Signaling](/mechanisms/tnf-alpha-signaling)
• [EGFR Signaling](/mechanisms/egfr-signaling)
• [ER Stress](/mechanisms/er-stress-unfolded-protein-response)
• [Protein Shedding](/mechanisms/protein-shedding)

External Links

• UniProt: [Q8IWP4](https://www.uniprot.org/uniprot/Q8IWP4)
• NCBI Gene: [84102](https://www.ncbi.nlm.nih.gov/gene/84102)
• PDB: [5IX2](https://www.rcsb.org/structure/5IX2), [5W5U](https://www.rcsb.org/structure/5W5U)
• GeneCards: [RHBDF2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RHBDF2)
• Ensembl: [ENSG00000158850](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158850)

See Also

• [Proteins Index](/proteins)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [TNF-α Signaling](/mechanisms/tnf-alpha-signaling)
• [ER Stress](/mechanisms/er-stress-unfolded-protein-response)

References